0000886163-22-000060.txt : 20220510
0000886163-22-000060.hdr.sgml : 20220510
20220510173335
ACCESSION NUMBER: 0000886163-22-000060
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220509
FILED AS OF DATE: 20220510
DATE AS OF CHANGE: 20220510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HIGGINS JOHN L
CENTRAL INDEX KEY: 0001208906
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 22911234
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD, SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2022-05-09
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001208906
HIGGINS JOHN L
5980 HORTON STREET, SUITE 405
EMERYVILLE
CA
94608
1
1
0
0
Chief Executive Officer
Common Stock
2022-05-09
4
M
0
8000
21.92
A
348593
D
0.75% Convertible Senior Notes due 2023
248.48
2022-05-10
4
S
0
450000
429159.38
D
2023-05-15
Common Stock
1811.0
725000
D
Non-Qualified Stock Option (right to buy)
21.92
2022-05-09
2022-05-09
4
M
0
8000
0.0
D
2023-02-15
Common Stock
8000
57616
D
The notes are convertible at any time prior to the close of business on November 14, 2022 (1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Issuer?s common stock on such trading day is greater than 130% of the conversion price on such trading day; (2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or (3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
By: Charles S. Berkman For: John L. Higgins
2022-05-10